Answers are grounded in this paper and cite their sources.
Post hoc analysis shows improved quality-adjusted survival in advanced HER2-negative gastric cancer, indicating better treatment outcomes.
AIMS: In KEYNOTE-859, pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with untreated locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, with manageable safety. This post hoc analysis assessed Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST). PARTICIPANTS AND METHODS: Survival time was grouped into three health states: TOX (time with any grade ≥3 adverse event [AE] before disease progression), TWiST (time before PD or death without grade ≥3 AEs), and REL (time from PD to death). Q-TWiST was the sum of restricted mean survival time (RMST) in each state, weighted by utilities estimated using the EQ-5D-5L questionnaire. Relative gains in Q-TWiST ≥15% were considered "clearly clinically important." RESULTS: RMST was longer in TOX (2.30 months [95% CI, 1.28 to 3.44]) and TWiST (1.90 months [95% CI, -0.02 to 3.79]) and shorter in REL (-0.28 months [95% CI, -2.43 to 2.01]) with pembrolizumab plus chemotherapy versus chemotherapy at month 56, for a relative Q-TWiST gain of 20.90% (US algorithm) or 18.38% (standardized algorithm). CONCLUSIONS: A clearly clinically important Q-TWiST gain was observed with pembrolizumab plus chemotherapy versus chemotherapy in all participants. CLINICAL TRIALS REGISTRATION: www.ClinicalTrials.gov identifier is NCT03675737.
No takes yet. Share an insight, caveat, or question.
Wyrwicz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: